Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.

Diabetes, obesity & metabolism

The Neuroendocrine-Appetite-Mental Health Triangle in PMOS: Implications for GLP-1 Receptor Agonist Therapy.

Neuroscience and biobehavioral reviews

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

BMJ (Clinical research ed.)

GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways.

Cell chemical biology

Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.

Drug metabolism and disposition: the biological fate of chemicals

Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial.

JACC. Heart failure

Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review.

Journal of diabetes

Brain Neuromodulation via Endoscopic Gastric Implant Improves Glycemic Control in Insulin-Dependent Type-2 Diabetes: First-in-Human Feasibility and Autonomic Response Study.

Journal of laparoendoscopic & advanced surgical techniques. Part A

Hims & Hers is going all-in on #peptides. Is $HIMS evolving from a GLP-1 to a peptide company? Let's discuss in the comments 👇 ❤️ Like 🟦 Save 🔁 Repost $HIMS is actively building operational capacity for peptide active pharmaceutical ingredient (API) production. The company https://t.co/YU99GqkJR5

Three things reshaping the peptide industry right now: • Medicare now covers GLP-1s for weight loss $50/mo, first time ever (launched July 1) • FDA panel decides July 23 on BPC-157, TB-500, Semax + 4 more • Novartis bet up to $1.7B on peptide drugs Federal access.

Top compounds on PeptideBase by provider coverage: 1. Semaglutide — 676 2. Tirzepatide — 444 3. BPC-157 — 402 4. NAD+ — 349 5. Sermorelin — 333 6. Ipamorelin — 320 7. CJC-1295 — 306 Coverage = where the market concentrated, not where the evidence is. Disclaimer: Research use

We just crossed 2,000 Reptides subscribers, and we're climbing fast. Reptides Briefs is core to what we're building. It's our editorial platform: a free monthly newsletter, plus a paid layer of deeper dives for premium members. We publish full dossiers on single peptides like

Who the July 23–24 peptide panel is made up of might be the biggest tell we have that the peptide bull market is just getting started. Reuters reported that 7 of the 14 panelists have ties to peptide clinics or peptide therapy businesses. If that’s not a sign that a handful of

We just crossed 2,000 Reptides subscribers, and we're climbing fast. Reptides Briefs is core to what we're building. It's our editorial platform: a free monthly newsletter, plus a paid layer of deeper dives for premium members. We publish full dossiers on single peptides like

@IhabFathiSulima The most likely reason is: > History of Medullary Thyroid Carcinoma (MTC) or MEN2 syndrome. ⚠️ Why? Ozempic (semaglutide), a GLP-1 receptor agonist, carries a boxed warning and is contraindicated in patients with: 🦋 Personal or family history of Medullary Thyroid Carcinoma

GLP/peptide talk translation: • “Gray market = sold outside authorized prescription/pharmacy channels. • “Research” = labeled “for research—not approved for human use” to enable sale in the US. • GLP-1 = the hormone pathway targeted by this drug class (Sema) • GLP-2 = https://t.co/jw0vVEq3xI